Linical and Accelovance have merged to create a market-leading, midsized, global contract research organization (CRO) with a significant footprint across North America, Europe and Asia-Pacific. As the next step in the merger, Accelovance has incorporated Linical into its name and will operate as Linical Accelovance Group, which includes Linical Accelovance Americas, Europe, Romania and China. Linical is the ideal partner for drug developers looking to expand their program into new markets. Linical offers a personalized, hands-on service approach across a variety of therapeutic areas and in all phases of development.

Linical Accelovance is an award winning, clinical development Contract Research Organization (CRO) focused on vaccine, oncology, dermatology, nutrition and women’s health (Phase I-IV programs). Providing global full CRO services to pharmaceutical companies, biotechs, CROs, and academic institutions; Linical Accelovance supports client needs by leveraging operational knowledge and patient recruitment strategies that result in successful clinical trials.

Linical Accelovance owns and operates a Clinical Call Center that assists in recruitment, retention, and surveillance. This knowledge, applied externally to sites and coupled with the therapeutic talent and experience of our team members, creates predictable, controlled enrollment and retention of quality patients ensuring study success. 

Linical Accelovance has been nominated for the Vaccine Industry Excellence’s (ViE) Best CRO Award 11 consecutive years and been awarded the title in 2009, 2010, and 2011; and received a “Highly Recommended” distinction in 2013. This external validation of Linical Accelovance’s vaccine research experience and success is a result of our ability to guarantee budgets, control timelines, and accelerate patient enrollment – delivering business solutions that address our clients’ clinical needs.

Established in 2005 with a corporate goal to deliver a personalized, hands-on service approach across a variety of therapeutic areas and in all phases of development, Linical Accelovance has made significant strides in the industry by combining strong business and operational perspective with clinical and medical expertise.


At Linical Accelovance, patients are of the utmost importance to us, so we do all we can to improve their experience and impact the future of health care around the world. Our priority is building relationships with our clients, so we can fully understand their needs. We give each of our projects thoughtful care and attention, because it is our goal to deliver innovative solutions for even the most difficult industry challenges.


We offer the same reach and experience as larger CROs, but maintain the personal, attentive service our clients expect. We do this by strategically growing our business, maintaining the most talented workforce available and approaching each project with care.

Core Values

Linical Accelovance has a reputation as the CRO that cares; not only about the success of clinical research programs, but also about improving patient care. Our customers benefit from an organization whose values are centered around strength as a unit, and a mission and vision focused on quality, success, innovation and communication. 

The Linical logo expresses our passion to pursue happiness of patients through our business activities.

    • Blue: integrity and honestyLogo-Linical_OK
    • Red: unending enthusiasm
    • Yellow: continuing spirit of inquiry

How can this level of performance from a committed CRO partner impact the journey of your next study?